Biological marker used for prediction of responsiveness of breast cancer patients on AT programme neoadjuvant chemotherapy

A technology for breast cancer, reactivity, applied in biomedicine

Active Publication Date: 2017-12-15
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Large-scale studies directly targeting patient plasma exosomes are in their infancy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological marker used for prediction of responsiveness of breast cancer patients on AT programme neoadjuvant chemotherapy
  • Biological marker used for prediction of responsiveness of breast cancer patients on AT programme neoadjuvant chemotherapy
  • Biological marker used for prediction of responsiveness of breast cancer patients on AT programme neoadjuvant chemotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Screening for miRNAs associated with responsiveness to neoadjuvant chemotherapy in breast cancer patients

[0051] 1. Research object

[0052] 1.1 Inclusion criteria

[0053] The study included samples of inpatients with luminal A breast cancer who received neoadjuvant chemotherapy at the Cancer Hospital of the Chinese Academy of Medical Sciences from October 2014 to December 2016 as the experimental group. Pathological immunohistochemical results showed luminal A type. Imaging examinations such as X-ray, CT, ultrasound, MRI, and whole-body bone imaging confirmed no distant metastasis, but local lymph node metastasis. All patients received 5 cycles of neoadjuvant chemotherapy with epirubicin + paclitaxel (AT) regimen.

[0054] 1.2 Collection of samples and clinical data

[0055] All patients were hospitalized in the Cancer Hospital of the Chinese Academy of Medical Sciences, and the resident physician collected medical history data, mainly including gender...

Embodiment 2

[0170] Example 2 Large sample verification differentially expressed miRNA

[0171] 1. 1. Research object

[0172] 1.1 Inclusion criteria

[0173] The study included samples of inpatients with luminal A breast cancer who received neoadjuvant chemotherapy at the Cancer Hospital of the Chinese Academy of Medical Sciences from October 2014 to December 2016 as the experimental group. Invasive carcinoma, pathological and immunohistochemical results showed luminal A type. Imaging examinations such as X-ray, CT, ultrasound, MRI, and whole-body bone imaging confirmed no distant metastasis, but local lymph node metastasis. All patients received 5 cycles of neoadjuvant chemotherapy with epirubicin + paclitaxel (AT) regimen. Among them, 50 patients were PR and 30 patients were SD.

[0174] 1.2 Collection of samples and clinical data

[0175] All patients were hospitalized in the Cancer Hospital of the Chinese Academy of Medical Sciences, and the resident physician collected medical h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a biological marker used for prediction of responsiveness of breast cancer patients on AT programme neoadjuvant chemotherapy. The biological marker is miR4772-3p. It is confirmed by experiments that: the miR-4772-3P expression level in blood exosome of curative effect SD group breast cancer patients is increased obviously compared with that of curative effect PR group breast cancer patients, so that miR4772-3p can be taken as the biological marker used for prediction of responsiveness of breast cancer patients on AT programme neoadjuvant chemotherapy. The research results can be used for providing guidance for development of therapeutic schedules of breast cancer patients by clinical doctors.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the use of miR-4772-3p in predicting the responsiveness of breast cancer patients to neoadjuvant chemotherapy. Background technique [0002] Exosomes are small vesicles with a molecular diameter of 30-100 nm produced during the fusion of cell membranes or multivesicular endosomes with cell membranes. distributed. In the study of exosome components, through further centrifugation and purification, it was found that exosomes are composed of lipid bilayers and contain a large number of proteins, nucleic acids and other components related to their cell origin. Proteins mainly include tetraspanins mainly composed of CD9, CD63, CD81 and CD82, fusion proteins such as Annexins and Flotillin, molecular chaperones and cytoskeleton proteins. And many proteins related to tumorigenesis and development, such as heat shock protein, tensin analogs, etc. The nucleic acids contained in exosomes mainly i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68A61K45/00A61P35/00
CPCA61K45/00C12Q1/6886C12Q2600/106C12Q2600/158C12Q2600/178
Inventor 徐兵河马飞瞿望翟晓宇李春晓
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap